Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.41 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.41 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16832441 | 0.89 | ASPH (0.46) | SLC2A1SLC2A2SLC2A3SLC2A4KDM4E | |
| SCHEMBL16832147 | 0.83 | NQO2 (0.60) | GRM2SLC2A1SLC2A2SLC2A3SLC2A4 | |
| SCHEMBL16832276 | 0.81 | GRM2 (0.49) | GRM2SLC2A1SLC2A3SLC2A4NQO2 | |
| SCHEMBL16832747 | 0.76 | GRM2 (0.51) | GRM2SLC2A1SLC2A2SLC2A3SLC2A4 | |
| SCHEMBL16832636 | 0.75 | NQO2 (0.50) | GRM2SLC2A1SLC2A3SLC2A4NQO2 | |
| SCHEMBL16832220 | 0.74 | DHODH (0.56) | GRM2NQO2KEAP1 | |
| SCHEMBL16833296 | 0.72 | NQO2 (0.56) | NQO2KDM4ELMNA | |
| SCHEMBL16833036 | 0.71 | GRM2 (0.48) | GRM2NQO2LMNAKEAP1NFE2L2 | |
| SCHEMBL16832661 | 0.71 | NQO2 (0.46) | GRM2SLC2A1SLC2A3SLC2A4NQO2 | |
| SCHEMBL16832509 | 0.69 | KDM4E (0.45) | GRM2KDM4EASPHKDM8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029647-A | Glucose transport inhibitors | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | GRM2 817/4885SLC2A1 1/4885SLC2A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.